Cargando…
Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2
BACKGROUND: Vaccination of young calves against Bovine viral diarrhea virus (BVDV) is desirable in dairy and beef operations to reduce clinical disease and prevent spread of the virus among cattle. Although protection from clinical disease by multivalent, modified-live virus (MLV) vaccines has been...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334402/ https://www.ncbi.nlm.nih.gov/pubmed/25880998 http://dx.doi.org/10.1186/s12917-015-0342-8 |
_version_ | 1782358181368823808 |
---|---|
author | Chamorro, Manuel F Walz, Paul H Passler, Thomas van Santen, Edzard Gard, Julie Rodning, Soren P Riddell, Kay P Galik, Patricia K Zhang, Yijing |
author_facet | Chamorro, Manuel F Walz, Paul H Passler, Thomas van Santen, Edzard Gard, Julie Rodning, Soren P Riddell, Kay P Galik, Patricia K Zhang, Yijing |
author_sort | Chamorro, Manuel F |
collection | PubMed |
description | BACKGROUND: Vaccination of young calves against Bovine viral diarrhea virus (BVDV) is desirable in dairy and beef operations to reduce clinical disease and prevent spread of the virus among cattle. Although protection from clinical disease by multivalent, modified-live virus (MLV) vaccines has been demonstrated, the ability of MLV vaccines to prevent viremia and viral shedding in young calves possessing passive immunity is not known. The purpose of this study was to compare the ability of three different MLV vaccines to prevent clinical disease, viremia, and virus shedding in early weaned beef calves possessing maternal immunity that were vaccinated once at 45 days prior to challenge with virulent BVDV 2. RESULTS: At 45 days following vaccination, calves that received vaccines B and C had significantly higher BVDV 1 and BVDV 2 serum antibody titers compared with control calves. Serum antibody titers for BVDV 1 and BVDV 2 were not significantly different between control calves and calves that received vaccine D. Following BVDV 2 challenge, a higher proportion of control calves and calves that received vaccine D presented viremia and shed virus compared with calves that received vaccines B and C. Rectal temperatures and clinical scores were not significantly different between groups at any time period. Calves that received vaccines B and C had significantly higher mean body weights at BVDV 2 challenge and at the end of the study compared with control calves. CONCLUSIONS: Moderate to low maternally-derived BVDV antibody levels protected all calves against severe clinical disease after challenge with virulent BVDV 2. Vaccines B and C induced a greater antibody response to BVDV 1 and BVDV 2, and resulted in reduced viremia and virus shedding in vaccinated calves after challenge indicating a greater efficacy in preventing virus transmission and reducing negative effects of viremia. |
format | Online Article Text |
id | pubmed-4334402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43344022015-02-20 Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2 Chamorro, Manuel F Walz, Paul H Passler, Thomas van Santen, Edzard Gard, Julie Rodning, Soren P Riddell, Kay P Galik, Patricia K Zhang, Yijing BMC Vet Res Research Article BACKGROUND: Vaccination of young calves against Bovine viral diarrhea virus (BVDV) is desirable in dairy and beef operations to reduce clinical disease and prevent spread of the virus among cattle. Although protection from clinical disease by multivalent, modified-live virus (MLV) vaccines has been demonstrated, the ability of MLV vaccines to prevent viremia and viral shedding in young calves possessing passive immunity is not known. The purpose of this study was to compare the ability of three different MLV vaccines to prevent clinical disease, viremia, and virus shedding in early weaned beef calves possessing maternal immunity that were vaccinated once at 45 days prior to challenge with virulent BVDV 2. RESULTS: At 45 days following vaccination, calves that received vaccines B and C had significantly higher BVDV 1 and BVDV 2 serum antibody titers compared with control calves. Serum antibody titers for BVDV 1 and BVDV 2 were not significantly different between control calves and calves that received vaccine D. Following BVDV 2 challenge, a higher proportion of control calves and calves that received vaccine D presented viremia and shed virus compared with calves that received vaccines B and C. Rectal temperatures and clinical scores were not significantly different between groups at any time period. Calves that received vaccines B and C had significantly higher mean body weights at BVDV 2 challenge and at the end of the study compared with control calves. CONCLUSIONS: Moderate to low maternally-derived BVDV antibody levels protected all calves against severe clinical disease after challenge with virulent BVDV 2. Vaccines B and C induced a greater antibody response to BVDV 1 and BVDV 2, and resulted in reduced viremia and virus shedding in vaccinated calves after challenge indicating a greater efficacy in preventing virus transmission and reducing negative effects of viremia. BioMed Central 2015-02-10 /pmc/articles/PMC4334402/ /pubmed/25880998 http://dx.doi.org/10.1186/s12917-015-0342-8 Text en © Chamorro et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Chamorro, Manuel F Walz, Paul H Passler, Thomas van Santen, Edzard Gard, Julie Rodning, Soren P Riddell, Kay P Galik, Patricia K Zhang, Yijing Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2 |
title | Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2 |
title_full | Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2 |
title_fullStr | Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2 |
title_full_unstemmed | Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2 |
title_short | Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2 |
title_sort | efficacy of multivalent, modified- live virus (mlv) vaccines administered to early weaned beef calves subsequently challenged with virulent bovine viral diarrhea virus type 2 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334402/ https://www.ncbi.nlm.nih.gov/pubmed/25880998 http://dx.doi.org/10.1186/s12917-015-0342-8 |
work_keys_str_mv | AT chamorromanuelf efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 AT walzpaulh efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 AT passlerthomas efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 AT vansantenedzard efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 AT gardjulie efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 AT rodningsorenp efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 AT riddellkayp efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 AT galikpatriciak efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 AT zhangyijing efficacyofmultivalentmodifiedlivevirusmlvvaccinesadministeredtoearlyweanedbeefcalvessubsequentlychallengedwithvirulentbovineviraldiarrheavirustype2 |